ERBB3 and breast carcinoma: There is growing awareness of the importance of HER2/HER3 heterodimer formation in breast cancer progression, where coexpression of HER2 and HER3 has been shown to be a poor prognostic indicator associated with resistance to endocrine therapy and to HER tyrosine kinase inhibitors [18-22].